ITEM VIEW

Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid

dc.contributor.authorCilliers K.
dc.contributor.authorLabadarios D.
dc.contributor.authorSchaaf H.S.
dc.contributor.authorWillemse M.
dc.contributor.authorMaritz J.S.
dc.contributor.authorWerely C.J.
dc.contributor.authorHussey G.
dc.contributor.authorDonald P.R.
dc.date.accessioned2011-05-15T16:15:13Z
dc.date.available2011-05-15T16:15:13Z
dc.date.issued2010
dc.identifier.citationActa Paediatrica, International Journal of Paediatrics
dc.identifier.citation99
dc.identifier.citation5
dc.identifier.issn08035253
dc.identifier.other10.1111/j.1651-2227.2010.01696.x
dc.identifier.urihttp://hdl.handle.net/10019.1/13243
dc.description.abstractAim: Little is known about pyridoxine nutriture of children treated with isoniazid (INH) regimens. This study documents plasma pyridoxal 5′-phosphate (PLP) concentrations in children, HIV-infected and HIV-uninfected, receiving INH regimens. Methods: Children from the Western Cape of South Africa hospitalized for tuberculosis (TB) management were studied. Plasma PLP concentrations were determined on enrolment, 1-month after commencing TB treatment, and again after 4-month's treatment. The children received a supplement meeting pyridoxine requirements. Results: Nineteen HIV-infected and 33 HIV-uninfected children received INH (dosage range 4-20 mg/kg) daily. Mean PLP plasma concentrations on enrolment were 8.32 (SD 6.75) ng/mL and 11.28 (SD 3.02) ng/mL in HIV-infected and HIV-uninfected children, respectively (p = 0.11) and after 4-month's treatment 6.75 (SD 2.71) ng/mL and 14.76 (SD 7.96) ng/mL (p < 0.001). On enrolment 9 (50%) HIV-infected and 5 (15%) HIV-uninfected children (p = 0.016) had suboptimal PLP concentrations (<6 ng/mL); after 4-month's treatment 8 (42%) and 2 (6%) (p = 0.004). Conclusion: Plasma PLP concentrations in children treated for TB were low on enrolment in HIV-infected and HIV-uninfected children; after 4-month's treatment low values were still common in HIV-infected children. Additional pyridoxine supplementation of malnourished children treated for tuberculosis is advisable, particularly those HIV-infected. © 2010 Foundation Acta Pædiatrica.
dc.subjectacyltransferase
dc.subjectefavirenz
dc.subjectethambutol
dc.subjectethionamide
dc.subjectisoniazid
dc.subjectisoniazid plus rifampicin
dc.subjectpyrazinamide
dc.subjectpyridoxal 5 phosphate
dc.subjectpyridoxine
dc.subjectrifampicin
dc.subjectrifater
dc.subjectrimcure
dc.subjectritonavir
dc.subjectunclassified drug
dc.subjectadolescent
dc.subjectarticle
dc.subjectchild
dc.subjectchildhood disease
dc.subjectcontrolled study
dc.subjectfemale
dc.subjecthuman
dc.subjectHuman immunodeficiency virus infection
dc.subjectinfant
dc.subjectlung tuberculosis
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmalnutrition
dc.subjectMycobacterium tuberculosis
dc.subjectoutcome assessment
dc.subjectpatient assessment
dc.subjectpreschool child
dc.subjectpriority journal
dc.subjectschool child
dc.subjectSouth Africa
dc.subjecttuberculous meningitis
dc.subjectvitamin blood level
dc.subjectvitamin supplementation
dc.subjectAdolescent
dc.subjectAIDS-Related Opportunistic Infections
dc.subjectAntitubercular Agents
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectFemale
dc.subjectGenotype
dc.subjectHIV Infections
dc.subjectHumans
dc.subjectInfant
dc.subjectIsoniazid
dc.subjectMale
dc.subjectPyridoxal Phosphate
dc.subjectSouth Africa
dc.subjectTuberculosis
dc.titlePyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW